Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imifoplatin - Promontory Therapeutics

Next Previous
Drug Profile

Imifoplatin - Promontory Therapeutics

Alternative Names: Phosphaplatin PT-112; PT-112

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio University
  • Developer EMD Serono; National Cancer Institute (USA); National Cheng Kung University; Pfizer; Promontory Therapeutics; SciClone Pharmaceuticals
  • Class Antineoplastics; Cyclohexanes; Diamines; Phosphoric acid esters; Platinum complexes; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant thymoma; Non-small cell lung cancer; Prostate cancer; Thymic epithelial tumour; Thymoma
  • Phase I/II Liver cancer; Solid tumours
  • No development reported Multiple myeloma

Most Recent Events

  • 20 May 2025 Promontory completed in person end of phase II (EOP2) meeting with the USFDA on phase III registrational study design
  • 20 May 2025 Promontary Therapeutics plans a phase III trial for Prostate cancer (Hormone refractory, Metastatic, Monotheray) (IV)
  • 20 May 2025 Promontory Therapeutics completes a phase II trial for Prostate cancer (Late-stage disease, Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA and France (IV) (NCT02266745)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top